Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

krka farma d.o.o. sarajevo - gentamicin - mast - 1 mg/1 g - 1 g masti sadrži: 1 mg gentamicin (u obliku gentamicinsulfata)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

krka farma d.o.o. sarajevo - gentamicin - otopina za injekciju - 80 mg/1 ampula - 2 ml otopine za injekciju sadrži: 80 mg gentamicina (u obliku gentamicinsulfata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - gentamicinum - mast - 1 mg/g - urbroj: 1 g masti sadrži 1 mg gentamicina u obliku gentamicinsulfata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - gentamicinsulfat - otopina za injekciju / infuziju - 120 mg/1,5 ml - urbroj: 1,5 ml otopine za injekciju ili infuziju (1 ampula) sadrži 120 mg gentamicina u obliku gentamicinsulfata; 1 ml otopine za injekciju ili infuziju sadrži 80 mg gentamicina u obliku gentamicinsulfata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - gentamicinsulfat - otopina za injekciju / infuziju - 80 mg/2 ml - urbroj: 2 ml otopine za injekciju (1 ampula) sadrži 80 mg gentamicina u obliku gentamicinsulfata 1 ml otopine za injekciju sadrži 40 mg gentamicina u obliku gentamicinsulfata

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

krka farma d.o.o. sarajevo - gentamicin - otopina za injekciju - 80 mg/1 ampula - 2 ml otopine za injekciju sadrži: 80 mg gentamicina (u obliku gentamicinsulfata)

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - Антитромбин alfa - nedostatak antitrombina iii - antitrombotska sredstva - atryn je indiciran za profilaksu venske tromboembolije u kirurgiji bolesnika s kongenitalnim nedostatkom antitrombina. atryn se normalno daje u kombinaciji s heparinom ili heparinom male molekulske mase.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorrhagics - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti za dermatitis, isključujući kortikosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

the medicines company uk ltd - Бивалирудин - akutni koronarni sindrom - antitrombotska sredstva - angiox predstavljena kao антикоагулянта kod odraslih pacijenata koji su patili чрескожное koronarne intervencije (ЧКВ), uključujući i kod bolesnika sa st-segmenta visina infarkta miokarda (stemi) prolazi primarni ЧКВ. angiox je također indiciran za liječenje odraslih bolesnika s nestabilnom anginom / nedostatak segmenta st инфарктом miokarda (val / ami bez elevacije st segmenta), planiranih za hitnu ili rane intervencije. angiox treba propisati aspirin i клопидогрел.